Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge
The Motley Fool
by newsfeedback@fool.com (Jonathan Ponciano)February 17, 2026
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/17/2026